This is the first study to develop a co-morbidity index for use with the Read/OXMIS coding system and the GPRD.
The Quality and Outcomes Framework (QOF) in UK primary care offers potential for developing a standardized morbidity score for low-risk populations.
A similar approach with results that seem promising was carried out by Geller et al. [ 23] in developing a severe morbidity score for the identification of near miss cases.
In an attempt to develop a regimen with less morbidity and equal efficacy, we conducted a phase I study of low-dose docetaxel plus cisplatin combined with radiation to determine an optimal dose of the chemotherapeutic reagents for a phase II study 6.
This study represents an important step forward in building on these discussions to develop a routine measure of co-morbidity.
During the study period, overall 0.85%% of eligible women admitted to the four study hospitals developed a severe maternal morbidity.
28 We also developed a composite neonatal morbidity outcome with the aim of identifying potential fetal stress during delivery.
From their review of the literature, Bayliss and colleagues [ 18] compiled a list of 24 health conditions most frequently assessed for the measurement of co-morbidity to develop an instrument for the assessment of disease burden.
For this reason we have developed a model that reduces morbidity and complications while enabling in vivo monitoring of bone healing.
Although knowledge of theoretical features, strengths and weaknesses of different approaches are fundamental for developing a predictive model of morbidity in the ICU, the final choice of model also has to consider the context and clinical scenario where the model will be used.
